Scott Clarke, Tizona CEO (Tizona)
July 21, 2020 08:30 AM EDTUpdated 10:09 AM
Deals

Gilead lines up a $1.55B biotech buy­out deal as CEO Dan O’Day in­vests in his lat­est can­cer block­buster dream

John Carroll

Editor & Founder

The Gilead BD team has teed up an­oth­er on­col­o­gy deal for CEO Dan O’Day.

This time the big biotech is rolling out a $300 mil­lion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Cal­tech spin­out de­buts with AI-dri­ven 'mir­ror pep­tide' plat­form

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times